Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Sucraid® Oral Solution to treat Congenital Sucrase-Isomaltase Deficiency (CSID)
Full IRB Study Title:
Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels
IRB Study ID: 2022-037
For complete details, please visit this study on Clinicaltrials.gov
Study Sponsor:
QOL Medical, LLC
Lead Investigator
Kevin Watson, MD, FAAP
Pediatric Gastroenterologist; Assistant Director, Clinical Informatics, Specialty Systems
Pediatric Gastroenterology
